Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children’s Oncology Group Bone Tumor Committee Consensus Statement
Matthew S. Dietz(Primary Children's Hospital), Kelly M. Bailey(University of Pittsburgh), Safia K. Ahmed(Mayo Clinic Hospital), Brian T. Craig(Children's Hospital of Wisconsin), Holcombe E. Grier(Harvard University), Christine M. Heske(National Institutes of Health), David S. Shulman(Harvard University), Elizabeth R. Lawlor(Center for Infectious Disease Research), Sarah Cohen‐Gogo(Hospital for Sick Children), Ryan D. Roberts(Nationwide Children's Hospital), Michael S. Isakoff(Center for Cancer and Blood Disorders), Patrick J. Grohar(National Institutes of Health), Damon R. Reed(Memorial Sloan Kettering Cancer Center), Jessica L. Davis(Indiana University School of Medicine), C. Matthew Hawkins(Emory University), Jesse K. Sandberg(Lucile Packard Children's Hospital), Alyaa Al‐Ibraheemi(Unknown), Ajay Gupta(Roswell Park Comprehensive Cancer Center), David S. Geller(Albert Einstein College of Medicine), Nicole I. Montgomery(Baylor College of Medicine), Katherine A. Janeway(Harvard University), Daniel J. Indelicato(University of Florida), Odion Binitie(Moffitt Cancer Center), Leo Mascarenhas(University of Southern California), Elyssa Rubin(Children's Hospital of Orange County), Susan L. Whiteway(Uniformed Services University of the Health Sciences), Mark Krailo(Arcadia), Catherine M. Albert(Les Hôpitaux de Chartres), Steven G. DuBois(University of California, San Francisco), Roshni Dasgupta(Cincinnati Children's Hospital Medical Center), Emily K. Slotkin(Memorial Sloan Kettering Cancer Center)
Cited by 9
Related Papers
K <sup>+</sup> Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension
|Science|2011|983
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
Institutional implementation of clinical tumor profiling on an unselected cancer population
|JCI Insight|2016|447
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419